Why the Delhi HC’s Take on Biosimilars May Set a Dangerous Precedent – SpicyIP
Why the Delhi HC’s Take on Biosimilars May Set a Dangerous Precedent – SpicyIP 1 In the past two months, Zydus Lifesciences has faced two legal setbacks in litigations for its biosimilar medicines. In April, the U.S. District Court of Delaware rejected Zydus’s challenge against the validity of Astellas’s patent on Myrbetriq, dealing a blow…